Human T-cell leukemia virus type 1 (HTLV-1), the first human oncogenic retrovirus that was originally described in 1980 [1], has been received much scientific attention due to its ability to transform primary T-lymphocytes in cell culture and its association with adult T-cell leukemia/lymphoma (ATL), a highly aggressive malignant proliferation of CD4+ T lymphocytes, and with tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/HAM), a distinct neurological disorder with inflammatory symptoms and incomplete paralysis of the limbs [2, 3]. Here, CD4 is linked to Myelopathy.